Participants at SPIEF-2026 believe Russia can succeed in the global pharmaceutical market by integrating AI, modern tech platforms, and regulatory/financial support. A key challenge identified is creating guaranteed demand for new drugs to attract investment.
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC Pharmaceutical and RemeGen have struck out-licensing agreements worth up to US$18.5 billion and US$5.6 billion respectively, while Haisco Pharmaceutical Group has added two of its own — most recently a deal worth up to US$745 million. Under the terms of the deal, the Beijing-based Haisco granted US...
